Hepatitis B virus (HBV) causes chronic infection in 250 million people worldwide. Chronic HBV carriers have a high risk of fibrosis, cirrhosis, and hepatocellular carcinoma. Drug resistance often develops during long-term antiviral treatment using HBV polymerase/reverse transcriptase inhibitors, making anti-HBV therapies as well as drug development more complicated. In this paper, a machine learning method based on large scale of gene expression profiles was used for anti-HBV drug screening.

Dataset Files

You must be an IEEE Dataport Subscriber to access these files. Subscribe now or login.

[1] xiaoyao yin, "Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.", IEEE Dataport, 2019. [Online]. Available: http://dx.doi.org/10.21227/5hyc-g775. Accessed: Jul. 14, 2024.
@data{5hyc-g775-19,
doi = {10.21227/5hyc-g775},
url = {http://dx.doi.org/10.21227/5hyc-g775},
author = {xiaoyao yin },
publisher = {IEEE Dataport},
title = {Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.},
year = {2019} }
TY - DATA
T1 - Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.
AU - xiaoyao yin
PY - 2019
PB - IEEE Dataport
UR - 10.21227/5hyc-g775
ER -
xiaoyao yin. (2019). Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.. IEEE Dataport. http://dx.doi.org/10.21227/5hyc-g775
xiaoyao yin, 2019. Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.. Available at: http://dx.doi.org/10.21227/5hyc-g775.
xiaoyao yin. (2019). "Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.." Web.
1. xiaoyao yin. Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo. [Internet]. IEEE Dataport; 2019. Available from : http://dx.doi.org/10.21227/5hyc-g775
xiaoyao yin. "Drug Repositioning: Sitagliptin as a Promising Anti-Hepatitis B Virus Drug Candidate In Silico, In Vitro, and In Vivo.." doi: 10.21227/5hyc-g775